Please login to the form below

Not currently logged in
Email:
Password:

Pfizer considers Icagen options

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in.

In a regulatory filing, Pfizer said Icagen representatives and Pfizer employees have engaged in preliminary discussions, and that Icagen had provided access to due diligence materials.

Pfizer said the continuing talks could lead to an extension or amendment of their longstanding agreement, including a change in its control "by means of a stock or asset acquisition or merger."

Icagen acknowledged that it is engaged in preliminary discussions with Pfizer, however, said there can be no assurance any agreement will be reached.

In 2007 Pfizer forged a research and licensing deal with Icagen, relating to medicines to treat pain and related disorders.

27th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics